Literature DB >> 24729341

Mutations in the exon 7 of Trp53 gene and the level of p53 protein in double transgenic mouse model of Alzheimer's disease.

Jolanta Dorszewska1, Anna Oczkowska, Monika Suwalska, Agata Rozycka, Jolanta Florczak-Wyspianska, Mateusz Dezor, Margarita Lianeri, Paweł P Jagodzinski, Michal J Kowalczyk, Michal Prendecki, Wojciech Kozubski.   

Abstract

Alzheimer's disease (AD) leads to generation of β-amyloid (Aβ) in the brain. Alzheimer's disease model PS/APP mice show a markedly accelerated accumulation of Aβ, which may lead to apoptosis induction e.g. in cells expressing wild-type p53. The TP53 gene is found to be the most frequently mutated gene in human tumour cells. There is accumulating evidence pointing out to the contribution of oxidative stress and chronic inflammation in both AD and cancer. The purpose of this study was to analyze exon 7 mutations of the murine Trp53 gene and Aβ/A4 and p53 protein levels in PS/APP and control mice. The studies were performed on female double transgenic PS/APP mice and young adults (8-12 weeks old) and age-matched control mice. The Trp53 mutation analysis was carried out with the use of PCR and DNA sequencing. The Aβ/A4 and p53 levels were analyzed by Western blotting. The frequency of mutations was almost quadrupled in PS/APP mice (44%), compared to controls (14%). PS/APP mice with the A929T and A857G mutations had a similar p53 level. In cerebral gray matter of PS/APP mice the level of p53 positive correlated with the level of Aβ protein (RS = +0.700, p < 0.05). In younger control animals, the T854G mutation was related to p53 down-regulation, while in aging ones, G859A substitution was most likely associated with over-expression of p53. In silico protein analysis revealed a possibly substantial impact of all four mutations on p53 activity. Three mutations were in close proximity to zinc-coordinating cysteine residues. It seems that in PS/APP mice missense Trp53 exon 7 mutations may be associated with the degenerative process by changes of p53 protein function.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24729341     DOI: 10.5114/fn.2014.41742

Source DB:  PubMed          Journal:  Folia Neuropathol        ISSN: 1509-572X            Impact factor:   2.038


  6 in total

1.  Network Pharmacology and Molecular Docking-Based Strategy to Investigate the Multitarget Mechanisms of Shenqi Yizhi Granule on Alzheimer's Disease.

Authors:  Linshuang Wang; Xiaoyu Xu; Zikang Wang; Qian Chen; Xiaodie Wei; Jingfan Xue; Zhanjun Zhang; Miao Wang; Yanping Li; Junying Zhang; Dongfeng Wei
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-30       Impact factor: 2.650

2.  Estimation of genomic instability and mutation induction by graphene oxide nanoparticles in mice liver and brain tissues.

Authors:  Hanan R H Mohamed; Mary Welson; Ahmed Essa Yaseen; Akmal A El-Ghor
Journal:  Environ Sci Pollut Res Int       Date:  2019-11-30       Impact factor: 4.223

3.  Resveratrol promotes hUC-MSCs engraftment and neural repair in a mouse model of Alzheimer's disease.

Authors:  Xinxin Wang; Shanshan Ma; Bo Yang; Tuanjie Huang; Nan Meng; Ling Xu; Qu Xing; Yanting Zhang; Kun Zhang; Qinghua Li; Tao Zhang; Junwei Wu; Greta Luyuan Yang; Fangxia Guan; Jian Wang
Journal:  Behav Brain Res       Date:  2017-11-02       Impact factor: 3.332

4.  Tau affects P53 function and cell fate during the DNA damage response.

Authors:  Martina Sola; Claudia Magrin; Giona Pedrioli; Sandra Pinton; Agnese Salvadè; Stéphanie Papin; Paolo Paganetti
Journal:  Commun Biol       Date:  2020-05-19

Review 5.  Interplay between MicroRNAs and Oxidative Stress in Neurodegenerative Diseases.

Authors:  Julia Konovalova; Dmytro Gerasymchuk; Ilmari Parkkinen; Piotr Chmielarz; Andrii Domanskyi
Journal:  Int J Mol Sci       Date:  2019-11-30       Impact factor: 5.923

Review 6.  Molecular crosstalk between cancer and neurodegenerative diseases.

Authors:  Jiyeon Seo; Mikyoung Park
Journal:  Cell Mol Life Sci       Date:  2019-12-28       Impact factor: 9.261

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.